White Matter Hyperintensities and Apolipoprotein E Affect the Association Between Mean Arterial Pressure and Objective and Subjective Cognitive Functioning in Older Adults
Restricted accessResearch articleFirst published online November 23, 2021
White Matter Hyperintensities and Apolipoprotein E Affect the Association Between Mean Arterial Pressure and Objective and Subjective Cognitive Functioning in Older Adults
White matter hyperintensities (WMH) show a robust relationship with arterial pressure as well as objective and subjective cognitive functioning. In addition, APOE ɛ4 carriership may influence how arterial pressure affects cognitive functioning.
Objective:
To determine the role of region-specific WMH burden and APOE ɛ4 carriership on the relationship between mean arterial pressure (MAP) and cognitive function as well as subjective cognitive decline (SCD).
Methods:
The sample consisted of 87 cognitively unimpaired middle-aged to older adults aged 50–85. We measured WMH volume for the whole brain, anterior thalamic radiation (ATR), forceps minor, and superior longitudinal fasciculus (SLF). We examined whether WMH burden mediated the relationship between MAP and cognition (i.e., TMT-A score for processing speed; Stroop performance for executive function) as well as SCD (i.e., Frequency of Forgetting (FoF)), and whether APOE ɛ4 carriership moderated that mediation.
Results:
WMH burden within SLF mediated the effect of MAP on Stroop performance. Both whole brain and ATR WMH burden mediated the effect of MAP on FoF score. In the MAP–WMH–Stroop relationship, the mediation effect of SLF WMH and the effect of MAP on SLF WMH were significant only in APOE ɛ4 carriers. In the MAP–WMH–FoF relationship, the effect of MAP on whole brain WMH burden was significant only in ɛ4 carriers.
Conclusion:
WMH burden and APOE genotype explain the link between blood pressure and cognitive function and may enable a more accurate assessment of the effect of high blood pressure on cognitive decline and risk for dementia.
TaylorWD, AizensteinHJ, AlexopoulosGS (2013) The vascular depression hypothesis: Mechanisms linking vascular disease with depression. Mol Psychiatry18, 963–974.
2.
PrinsND, ScheltensP (2015) White matter hyperintensities, cognitive impairment and dementia: An update. Nat Rev Neurol11, 157–165.
3.
ChutinetA, RostNS (2014) White matter disease as a biomarker for long-term cerebrovascular disease and dementia topical collection on cerebrovascular disease and stroke. Curr Treat Options Cardiovasc Med16, 292.
4.
KnopmanD, BolandLL, MosleyT, HowardG, LiaoD, SzkloM, McGovernP, FolsomAR (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology56, 42–48.
5.
ZhuL, ViitanenM, GuoZ, WinbladB, FratiglioniL (1998) Blood pressure reduction, cardiovascular diseases, and cognitive decline in the Mini-Mental State Examination in a community population of normal very old people: A three-year follow-up. J Clin Epidemiol51, 385–391.
6.
VanVliet P (2012) Cholesterol and late-life cognitive decline. J Alzheimers Dis30(Suppl 2), S147–162.
7.
Van Den BergE, GeerlingsMI, BiesselsGJ, NederkoornPJ, KloppenborgRP (2018) White matter hyperintensities and cognition in mild cognitive impairment and Alzheimer’s disease: A domain-specific meta-analysis. J Alzheimers Dis63, 515–527.
8.
KloppenborgRP, NederkoornPJ, GeerlingsMI, VanDen Berg E (2014) Presence and progression of white matter hyperintensities and cognition: A meta-analysis. Neurology82, 2127–2138.
9.
WallinA, SjögrenM, EdmanÅ, BlennowK, ReglandB (2000) Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol44, 229–235.
10.
MurrayAD, StaffRT, ShenkinSD, DearyIJ, StarrJM, WhalleyLJ (2005) Brain white matter hyperintensities: Relative importance of vascular risk factors in nondemented elderly people. Radiology237, 251–257.
11.
WardlawJM, Valdés HernándezMC, Muñoz-ManiegaS (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc4, 001140.
12.
FazekasF, KleinertR, OffenbacherH, SchmidtR, KleinertG, PayerF, RadnerH, LechnerH (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology43, 1683–1689.
13.
TomimotoH, AkiguchiI, SuenagaT, NishimuraM, WakitaH, NakamuraS, KimuraJ (1996) Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer’s disease patients. Stroke27, 2069–2074.
14.
YoungVG, HallidayGM, KrilJJ (2008) Neuropathologic correlates of white matter hyperintensities. Neurology71, 804–811.
15.
Muñoz ManiegaS, ChappellFM, Valdés HernándezMC, ArmitagePA, MakinSD, HeyeAK, ThrippletonMJ, SakkaE, ShulerK, DennisMS, WardlawJM (2017) Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease. J Cereb Blood Flow Metab37, 644–656.
16.
GriffantiL, JenkinsonM, SuriS, ZsoldosE, MahmoodA, FilippiniN, SextonCE, TopiwalaA, AllanC, KivimäkiM, Singh-ManouxA, EbmeierKP, MackayCE, ZamboniG (2018) Classification and characterization of periventricular and deep white matter hyperintensities on MRI: A study in older adults. Neuroimage170, 174–181.
17.
JongenC, van der GrondJ, KappelleLJ, BiesselsGJ, ViergeverMA, PluimJP; Utrecht Diabetic Encephalopathy Study Group (2007) Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia50, 1509–1516.
LampeL, ZhangR, BeyerF, HuhnS, Kharabian MasoulehS, PreusserS, BazinPL, SchroeterML, VillringerA, WitteAV (2019) Visceral obesity relates to deep white matter hyperintensities via inflammation. Ann Neurol85, 194–203.
21.
GuoX, PantoniL, SimoniM, BengtssonC, BjörkelundC, LissnerL, GustafsonD, SkoogI (2009) Blood pressure components and changes in relation to white matter lesions. Hypertension54, 57–62.
22.
MarcusJ, GardenerH, RundekT, ElkindMSV, SaccoRL, DecarliC, WrightCB (2011) Baseline and longitudinal increases in diastolic blood pressure are associated with greater white matter hyperintensity volume: The Northern Manhattan Study. Stroke42, 2639–2641.
23.
TsaoCW, HimaliJJ, BeiserAS, LarsonMG, DecarliC, VasanRS, MitchellGF, SeshadriS (2016) Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology86, 619–626.
24.
DufouilC, de Kersaint-GillyA, BesanconV, LevyC, AuffrayE, BrunnereauL, AlperovitchA, TzourioC (2001) Longitudinal study of blood pressure and white matter hyperintensities: The EVA MRI Cohort. Neurology56, 921–926.
25.
JacobsHIL, VisserPJ, Van BoxtelMPJ, FrisoniGB, TsolakiM, PapapostolouP, NobiliF, WahlundLO, MinthonL, FrölichL, HampelH, SoininenH, van de PolL, ScheltensP, TanFES, JollesJ, VerheyFRJ (2012) The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiol Aging33, 201.e1–8.
26.
HirsigerS, KoppelmansV, MérillatS, ErdinC, NarkhedeA, BrickmanAM, JänckeL (2017) Executive functions in healthy older adults are differentially related to macro- and microstructural white matter characteristics of the cerebral lobes. Front Aging Neurosci9, 1–14.
27.
Van Den HeuvelDMJ, Ten DamVH, De CraenAJM, Admiraal-BehloulF, OlofsenH, BollenELEM, JollesJ, MurrayHM, BlauwGJ, WestendorpRGJ, Van BuchemMA (2006) Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry77, 149–153.
28.
DebetteS, MarkusHS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ341, c3666–c3666.
29.
BrickmanAM (2013) Contemplating Alzheimer’s disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep13, 415.
30.
WangR, FratiglioniL, KalpouzosG, LövdénM, LaukkaEJ, BrongeL, WahlundLO, BäckmanL, QiuC (2017) Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: A population-based study. Alzheimers Dement13, 247–256.
31.
BiesbroekJM, KuijfHJ, Van der GraafY, VinckenKL, PostmaA, MaliWPTM, BiesselsGJ, GeerlingsMI (2013) Association between subcortical vascular lesion location and cognition: A voxel-based and tract-based lesion-symptom mapping study. The SMART-MR Study. PLoS One8, e60541.
32.
BiesbroekJM, WeaverNA, HilalS, KuijfHJ, IkramMK, XuX, TanBY, VenketasubramanianN, PostmaA, BiesselsGJ, ChenCPLH (2016) Impact of strategically located white matter hyperintensities on cognition in memory clinic patients with small vessel disease. PLoS One11, e0166261.
33.
DueringM, GesierichB, SeilerS, PirpamerL, GonikM, HoferE, JouventE, DuchesnayE, ChabriatH, RopeleS, SchmidtR, DichgansM (2014) Strategic white matter tracts for processing speed deficits in age-related small vessel disease. Neurology82, 1946–1950.
34.
DueringM, ZierenN, HervéD, JouventE, ReyesS, PetersN, PachaiC, OpherkC, ChabriatH, DichgansM (2011) Strategic role of frontal white matter tracts in vascular cognitive impairment: A voxel-based lesion-symptom mapping study in CADASIL. Brain134, 2366–2375.
35.
JiangJ, ParadiseM, LiuT, ArmstrongNJ, ZhuW, KochanNA, BrodatyH, SachdevPS, WenW (2018) The association of regional white matter lesions with cognition in a community-based cohort of older individuals. Neuroimage Clin19, 14–21.
36.
AttemsJ, JellingerKA (2014) The overlap between vascular disease and Alzheimer’s disease - lessons from pathology. BMC Med12, 206.
37.
KloppenborgRP, Van den BergE, KappelleLJ, BiesselsGJ (2008) Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. Eur J Pharmacol585, 97–108.
38.
BuckleyRF, HanseeuwB, SchultzAP, VanniniP, AghjayanSL, ProperziMJ, JacksonJD, MorminoEC, RentzDM, SperlingRA, JohnsonKA, AmariglioRE (2017) Region-specific association of subjective cognitive decline with tauopathy independent of global β-amyloid burden. JAMA Neurol74, 1455–1463.
DufouilC, FuhrerR, AlpérovitchA (2005) Subjective cognitive complaints and cognitive decline: Consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc53, 616–621.
41.
ReisbergB, ShulmanMB, TorossianC, LengL, ZhuW (2010) Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement6, 11–24.
42.
JessenF, WieseB, BachmannC, Eifflaender-GorferS, HallerF, KölschH, LuckT, MöschE, van den BusscheH, WagnerM, others (2010) Prediction of dementia by subjective memory impairment: Effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry67, 414–422.
43.
Van RoodenS, Van Den Berg-HuysmansAA, CrollPH, LabadieG, HayesJM, VivianoR, Van Der GrondJ, RomboutsSARB, DamoiseauxJS (2018) Subjective cognitive decline is associated with greater white matter hyperintensity volume. J Alzheimers Dis66, 1283–1294.
44.
VerghesePB, CastellanoJM, HoltzmanDM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol10, 241–252.
45.
BrickmanAM, SchupfN, ManlyJJ, SternY, LuchsingerJA, ProvenzanoFA, NarkhedeA, RazlighiQ, Collins-PrainoL, ArteroS, AkbaralyTN, RitchieK, MayeuxR, PortetF (2014) APOE ɛ4 and risk for Alzheimer’s disease: Do regionally distributed white matter hyperintensities play a role?Alzheimers Dement10, 619–629.
ShaabanCE, AizensteinHJ, JorgensenDR, MacCloudRL, MeckesNA, EricksonKI, GlynnNW, MettenburgJ, GuralnikJ, NewmanAB, IbrahimTS, LaurientiPJ, VallejoAN, RosanoC (2017) In vivo imaging of venous side cerebral small-vessel disease in older adults: An MRI method at 7T. Am J Neuroradiol38, 1923–1928.
50.
De LeeuwFE, RichardF, De GrootJC, Van DuijnCM, HofmanA, Van GijnJ, BretelerMMB (2004) Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke35, 1057–1060.
51.
LivnyA, Ravona-SpringerR, HeymannA, PriessR, KushnirT, TsarfatyG, RabinovL, MoranR, HoffmanH, CooperI, GreenbaumL, SilvermanJ, SanoM, JohnsonSC, BendlinBB, BeeriMS (2016) Long-term variability in glycemic control is associated with white matter hyperintensities in APOE4 genotype carriers with type 2 diabetes. Diabetes Care39, 1056–1059.
52.
SafarME, BoudierHS (2005) Vascular development, pulse pressure, and the mechanisms of hypertension. In Hypertension, pp. 205-209.
53.
MayetJ, HughesA (2003) Pathophysiology in hypertension. Hear J89, 1104–1109.
54.
BiesbroekJM, WeaverNA, BiesselsGJ (2017) Lesion location and cognitive impact of cerebral small vessel disease. Clin Sci131, 715–728.
55.
TombaughTN, MclntyreNJ (1992) The Mini-Mental State Examination: A comprehensive review. Prog Geriatr40, 922–935.
56.
LoewensteinDA, AcevedoA, OwnbyR, AgronJ, BarkerWW, IsaacsonR, StraumanS, DuaraR (2006) Using different memory cutoffs to assess mild cognitive impairment. Am J Geriatr Psychiatry14, 911–919.
57.
BrooksBL, IversonGL, HoldnackJA, FeldmanHH (2008) Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults. J Int Neuropsychol Soc14, 463–478.
58.
MistridisP, EgliSC, IversonGL, BerresM, WillmesK, Welsh-BohmerKA, MonschAU (2015) Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer’s Disease-Neuropsychological Assessment Battery (CERAD). Eur Arch Psychiatry Clin Neurosci265, 407–417.
59.
WerryAE, DanielM, BergströmB (2019) Group differences in normal neuropsychological test performance for older non-Hispanic White and Black/African American adults. Neuropsychology33, 1089–1100.
60.
ManlyJJ, JacobsDM, SanoM, BellK, MerchantCA, SmallSA, SternY (1998) Cognitive test performance among nondemented elderly African Americans and whites. Neurology50, 1238–1245.
61.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
62.
WechslerD (2008) Wechsler memory scale–fourth edition (WMS-IV) technical and interpretive manual, Pearson, San Antonio, TX.
63.
CorderEH, SaundersAM, RischNJ, StrittmatterWJ, SchmechelDE, GaskellPC, RimmlerJB, LockePA, ConneallyPM, SchmaderKE, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet7, 180–184.
64.
BennetAM, Di AngelantonioE, YeZ, WensleyF, DahlinA, AhlbomA, KeavneyB, CollinsR, WimanB, DeFaire U, DaneshJ (2007) Association of apolipoprotein e genotypes with lipid levels and coronary risk. J Am Med Assoc298, 1300–1311.
65.
ReitanRM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills8, 271–276.
66.
StroopJR (1935) Studies of interference in serial verbal reactions. J Exp Psychol18, 643.
67.
ValentijnSAM, Van BoxtelMPJ, Van HoorenSAH, BosmaH, BeckersHJM, PondsRWHM, JollesJ (2005) Change in sensory functioning predicts change in cognitive functioning: Results from a 6-year follow-up in the Maastricht Aging Study. J Am Geriatr Soc53, 374–380.
68.
GilewskiMJ, ZelinskiEM, SchaieKW (1990) The Memory Functioning Questionnaire for assessment of memory complaints in adulthood and old age. Psychol Aging5, 482–490.
69.
JenkinsonM, PechaudM, SmithS (2005) BET2: MR-based estimation of brain, skull and scalp surfaces. In Eleventh annual meeting of the organization for human brain mapping, pp. 167.
70.
SchmidtP (2017) Bayesian inference for structured additive regression models for large-scale problems with applications to medical imaging, Doctoral dissertation. Ludwig-Maximilians-Universität München, Germany.
71.
GriffantiL, ZamboniG, KhanA, LiL, BonifacioG, SundaresanV, SchulzUG, KukerW, BattagliniM, RothwellPM, JenkinsonM (2016) BIANCA (Brain Intensity AbNormality Classification Algorithm): A new tool for automated segmentation of white matter hyperintensities. Neuroimage141, 191–205.
72.
HuaK, ZhangJ, WakanaS, JiangH, LiX, ReichDS, CalabresiPA, PekarJJ, van ZijlPCM, MoriS (2008) Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification. Neuroimage39, 336–347.
73.
TabachnickBG, FidellLS (2013) Using Multivariate Statistics, Pearson, Boston, MA, pp. 73.
74.
HayesAF (2018) Introduction to mediation, moderation, and conditional process analysis: A regression-based approach, Guilford publications, New York, NY.
75.
CampbellKL, GradyCL, NgC, HasherL (2012) Age differences in the frontoparietal cognitive control network: Implications for distractibility. Neuropsychologia50, 2212–2223.
76.
BangenKJ, BeiserA, Delano-WoodL, NationDA, LamarM, LibonDJ, BondiMW, SeshadriS, WolfPA, AuR (2013) APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis22, 1361–1369.
77.
PantoniL, GarciaJH (1997) Pathogenesis of leukoaraiosis: A review. Stroke28, 652–659.
